Gradientech

About this entry

To prevent antibiotic resistance, healthcare providers should prescribe antibiotics correctly, i.e. start the right drug as soon as possible at the right dose, based on knowledge about bacterial species and antibiotic susceptibility pattern from patient samples. AST results within short times and with high precision are demanded, especially for blood infections (sepsis) where every hour before appropriate therapy is initiated, increases mortality and hospital costs. Our patent pending QuickMIC™ method generates rapid phenotypic AST results, including precise MIC values – currently a full day before the golden standard macrodilution and Etest. Evaluation with clinical blood samples is ongoing in close collaboration with the Antibiotics Research Unit at Uppsala University headed by Prof. Otto Cars, and the Dep. of Clinical Microbiology at Uppsala University Hospital, Sweden.QuickMIC™ was recently attentived by the Swedish Innovation Agency Vinnova and grant financed.

Based on our patent-pending and proprietary microfluidic technology solution to create stable substance gradients, Gradientech is developing an in vitro diagnostic solution for rapid antibiotic susceptibility testing of positive blood culture samples. By real-time monitoring of bacterial growth and quantification of micro-colonies within precise antibiotic gradients, phenotypic susceptibility guidance is maintained within only 2 hours. This is at least 22 hours faster compared to traditional culture-based methods used for AST in clinics today.

If you would like to be introduced to this team for collaboration, get in touch with the Longitude prize.